Assess whether the primary endpoint will survive FDA scrutiny (802520)

SITUATION Pharmacovigilance medical reviewer owns this Pharmacovigilance review in a labeling team facing a boxed-warning debate. A boxed-warning proposal from the review division is the triggering event; advisory-committee question list that exposes a weak secondary endpoint is the evidence for whether the primary endpoint will survive FDA scrutiny.

DECISION Pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. The population in advisory-committee question list that exposes a weak secondary endpoint is the one a boxed-warning proposal from the review division named, so Proceed under protocol follows for this Pharmacovigilance file. 2. The population in advisory-committee question list that exposes a weak secondary endpoint is adjacent only to a boxed-warning proposal from the review division; Pause the pathway is the honest Pharma & Life Sciences call. 3. A labeling team facing a boxed-warning debate already contained a boxed-warning proposal from the review division before advisory-committee question list that exposes a weak secondary endpoint arrived; no new Pharmacovigilance path. 4. Provenance on advisory-committee question list that exposes a weak secondary endpoint after a boxed-warning proposal from the review division is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 2. Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim pharmacovigilance medical reviewer would keep. 3. Map FDA-response timing and owner in a labeling team facing a boxed-warning debate. 4. For this Pharma & Life Sciences Pharmacovigilance file, read advisory-committee question list that exposes a weak secondary endpoint against a boxed-warning proposal from the review division and write the one fact that would move the primary endpoint will for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (advisory-committee question list that exposes a weak secondary endpoint after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option advisory-committee question list that exposes a weak secondary endpoint can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate.